BioSpace News Archive

EVERSANA will join a trusted network of more than 1,300 research-oriented organisations, many of which develop therapeutic solutions for rare diseases as well as cell and gene therapies, to continue to provide innovative patient-centric solutions throughout Europe.

OMass Therapeutics, a biotechnology company identifying medicines against highly validated target ecosystems, unveiled its pipeline of five novel, differentiated small molecule drug programs, targeting intractable or inadequately drugged membrane and complex-bound protein targets such as GPCRs, solute carriers and intracellular protein complexes.

Berkeley Lights, Inc., a leader in Digital Cell Biology, reported financial results for the quarter ended September 30, 2021.

Global health services company Cigna Corporation reported third quarter 2021 results with strong revenue and earnings growth across its businesses.

DaVita Clinical Research will present eight research abstracts from company representatives and medical professionals during the American Society of Nephrology Kidney Week occurring Nov. 4–7, 2021.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its Q3 2021 financial results for the periods ended September 30, 2021 and provided a corporate update.

Nordic Nanovector ASA, a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives of patients with haematological cancers, will host an R&D Day on Tuesday, 30 November 2021 at 14:00 CET/ 13:00 GMT/ 08:00 ET.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a collaboration with IMPACT Therapeutics where Burning Rock provides testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064

Targovax ASA, a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces its third quarter 2021 results.